The disconnect between phase II and phase III trials of drugs for heart failure

The Association Between Hospital Volume and Processes, Outcomes, and Costs of Care for Congestive Heart Failure

(2013) Karen E. Joynt et al.   ANNALS OF INTERNAL MEDICINE

Bayesian adaptive trial design in acute heart failure syndromes: Moving beyond the mega trial

(2012) Sean P. Collins et al.   AMERICAN HEART JOURNAL

Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes

(2012) Mihai Gheorghiade et al.   EUROPEAN JOURNAL OF HEART FAILURE

Thirty-Day Readmissions — Truth and Consequences

(2012) Karen E. Joynt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Heart Disease and Stroke Statistics—2012 Update

(2011) et al.   CIRCULATION

Beyond dyspnoea as an endpoint in acute heart failure trials

(2011) M. Gheorghiade et al.   EUROPEAN HEART JOURNAL

Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial

(2011) J. E. A. Blair et al.   EUROPEAN HEART JOURNAL

A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial

(2011) Mihai Gheorghiade et al.   HEART FAILURE REVIEWS

Improving Postdischarge Outcomes in Patients Hospitalized for Acute Heart Failure Syndromes

(2011) Mihai Gheorghiade   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

National and Regional Trends in Heart Failure Hospitalization and Mortality Rates for Medicare Beneficiaries, 1998-2008

(2011) Jersey Chen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of Nesiritide in Patients with Acute Decompensated Heart Failure

(2011) C.M. O'Connor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: Results from efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) program

(2010) Christopher M. O'Connor et al.   AMERICAN HEART JOURNAL

Postdischarge Assessment After a Heart Failure Hospitalization

(2010) Marco Metra et al.   CIRCULATION

Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes

(2010) G. Michael Felker et al.   Circulation-Heart Failure

Trends in Length of Stay and Short-term Outcomes Among Medicare Patients Hospitalized for Heart Failure, 1993-2006

(2010) Héctor Bueno   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Early follow-up after hospitalization for heart failure

(2010) Mihai Gheorghiade et al.   Nature Reviews Cardiology

Rolofylline, an Adenosine A1−Receptor Antagonist, in Acute Heart Failure

(2010) Barry M. Massie et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group

(2009) Mihai Gheorghiade et al.   AMERICAN HEART JOURNAL

2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults

(2009) et al.   CIRCULATION

Recent National Trends in Readmission Rates After Heart Failure Hospitalization

(2009) Joseph S. Ross et al.   Circulation-Heart Failure

Effects of tolvaptan on dyspnoea relief from the EVEREST trials

(2009) P. S. Pang et al.   EUROPEAN HEART JOURNAL

The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study

(2009) A. Mebazaa et al.   EUROPEAN HEART JOURNAL

Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial

(2009) J. E.A. Blair et al.   EUROPEAN HEART JOURNAL

Acute Heart Failure Syndromes

(2009) Mihai Gheorghiade et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study

(2009) John R Teerlink et al.   LANCET

Tolvaptan

(2009) Jalal K. Ghali et al.   NATURE REVIEWS DRUG DISCOVERY

Rehospitalizations among Patients in the Medicare Fee-for-Service Program

(2009) Stephen F. Jencks et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early and Long-term Outcomes of Heart Failure in Elderly Persons, 2001-2005

(2008) Lesley H. Curtis et al.   ARCHIVES OF INTERNAL MEDICINE

A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach

(2008) P. S. Pang et al.   EUROPEAN HEART JOURNAL

The PROTECT Pilot Study: A Randomized, Placebo-Controlled, Dose-Finding Study of the Adenosine A1 Receptor Antagonist Rolofylline in Patients With Acute Heart Failure and Renal Impairment

(2008) Gad Cotter et al.   JOURNAL OF CARDIAC FAILURE

Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients With Symptomatic Heart Failure and Systolic Dysfunction

(2008) James E. Udelson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY